2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
Yasuaki SagaraHiraku KumamaruNaoki NiikuraMinoru MiyashitaTakaaki KonishiTakayuki IwamotoNaoko SanukiKenta TanakuraMasayuki NagahashiNaoki HayashiMasayuki YoshidaNaoko KinukawaChie WatanabeMasakazu ToiShigehira SajiPublished in: Breast cancer (Tokyo, Japan) (2024)
The Japanese Breast Cancer Society initiated the breast cancer registry in 1975, which transitioned to the National Clinical Database-Breast Cancer Registry in 2012. This annual report presents data from 2020 and analyzes the ten-year mortality rates for those aged 65 and older. We analyzed data from 93,784 breast cancer (BC) cases registered in 2020 and assessed 10-year mortality rates for 36,279 elderly patients diagnosed between 2008 and 2012. In 2020, 99.4% of BC cases were females with a median age of 61. Most (65%) were diagnosed at early stages (Stage 0 or I). Breast-conserving surgery rates varied with stages: 58.5% at cStage I, 30.8% at cStage II, and 13.1% at cStage III. Sentinel lymph node biopsy was done in 73.6% of cases, followed by radiotherapy in 70% of those post-conserving surgery and chemotherapy in 21.1% post-surgery. Pathology showed that 63.4% had tumors under 2.0 cm, 11.7% had pTis tumors, and 77.3% had no axillary lymph node metastasis. ER positivity was seen in 75.1%, HER2 in 14.3%, and 30% had a Ki67 positivity rate above 30%. Across all stages and subtypes, there was a trend where the 10-year mortality rates increased for individuals older than 65 years. In Stage I, many deaths were not directly linked to BC and, for those with HER2-type and triple-negative BC, breast cancer-related deaths increased with age. Within Stage II, patients older than 70 years with luminal-type BC often experienced deaths not directly linked to BC, whereas patients below 80 years with HER2-type and triple-negative BC, likely had breast cancer-related deaths. In Stage III, breast cancer-related deaths were more common, particularly in HER2 and triple-negative BC. Our prognostic analysis underscores distinct mortality patterns by stage, subtype, and age in elderly BC patients. It highlights the importance of personalized treatment strategies, considering subtype-specific aggressiveness, age-related factors, and comorbidities.
Keyphrases
- sentinel lymph node
- ejection fraction
- cardiovascular events
- minimally invasive
- newly diagnosed
- lymph node metastasis
- middle aged
- neoadjuvant chemotherapy
- early stage
- physical activity
- lymph node
- community dwelling
- squamous cell carcinoma
- risk factors
- prognostic factors
- type diabetes
- young adults
- patient reported outcomes
- radiation therapy
- locally advanced
- electronic health record
- coronary artery disease
- estrogen receptor
- data analysis
- patient reported
- percutaneous coronary intervention
- breast cancer risk
- endoplasmic reticulum